SCHEMBL29327624

SCHEMBL29327624

Cc1ccccc1-c1nc2cc(NC(=O)c3nc(C#N)ccc3S(C)(=O)=O)ccc2o1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.58
▸ NPC1 O15118 5/20 0.54
▸ RAB9A P51151 5/20 0.54
▸ TP53 P04637 8/20 0.50
▸ SMN1; SMN2 Q16637 5/20 0.50
▸ PPARG P37231 1/20 0.50
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ PTGES O14684 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ NFKB1 P19838 2/20 0.46
▸ NFKB2 Q00653 2/20 0.46
▸ RELA Q04206 2/20 0.46
▸ HSD17B10 Q99714 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ RXFP1 Q9HBX9 2/20 0.44
▸ PTGS2 P35354 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327628 0.91 MAPT (0.59) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327620 0.86 TP53 (0.54) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327616 0.85 TP53 (0.56) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327743 0.85 MAPT (0.57) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327584 0.84 MAPT (0.58) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327627 0.83 MAPT (0.57) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327637 0.83 PPARG (0.52) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327625 0.82 PPARG (0.60) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327646 0.79 PPARG (0.53) MAPTNPC1RAB9ATP53SMN1; SMN2
SCHEMBL29327815 0.78 MAPT (0.57) MAPTNPC1RAB9ATP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD MAPT 4591/4885NPC1 695/4885RAB9A 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback